GB800

GB800 is an investigational strontium-based small molecule developed by Galleon Bio for the treatment of neuropathic pain and inflammatory skin diseases. As a 'next-generation' candidate in Galleon Bio's pipeline, GB800 utilizes the company's proprietary technology to deliver strontium ions, which act as divalent cation modulators. The drug is designed to provide therapeutic effects by antagonizing the Transient Receptor Potential Vanilloid 1 (TRPV1) channel and activating the Calcium-Sensing Receptor (CaSR). This dual mechanism aims to inhibit the transmission of pain signals and reduce the release of pro-inflammatory cytokines, offering a non-opioid and non-steroidal alternative for chronic dermatological and neurological conditions.